Recent performance snapshot
National Health Investors (NHI) has drawn attention after a one-month return of about a 9% decline and a past three-month return of roughly a 7% decline, against a last close of US$75.71.
See our latest analysis for National Health Investors.
That recent share price weakness, including the 1-month share price return of about a 9% decline, contrasts with a 1-year total shareholder return of 4.43% and a very large 79.88% total shareholder return over three years. This suggests momentum has cooled after a strong multi year run.
If you are weighing NHI against other opportunities in income focused sectors, it can help to see what else is attracting attention among listed real estate and infrastructure plays through the 36 power grid technology and infrastructure stocks
With NHI trading at US$75.71, sitting at a reported 56% discount to one intrinsic value estimate and a 17% gap to analyst targets, you have to ask: is this genuine value or is future growth already priced in?
Most Popular Narrative: 15% Undervalued
The most followed narrative pegs National Health Investors' fair value at about $89, compared with the recent close at $75.71, framing the current discount and the assumptions behind it.
NHI's focused expansion of its SHOP (Senior Housing Operating Portfolio) segment, with double-digit NOI growth projected and a robust pipeline of accretive acquisitions, positions the company for outsized multi-year NOI and earnings growth relative to peers.
Want to see what sits underneath that optimism on SHOP and earnings power. One revenue growth path, one margin profile, one future earnings multiple. The full narrative spells out how those moving parts combine to support a fair value that sits well above today's price.
Result: Fair Value of $89 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that bullish fair value story also leans heavily on smoother SHOP occupancy trends and consistent acquisition execution, both of which recent commentary has described as uncertain.
Find out about the key risks to this National Health Investors narrative.
Next Steps
With mixed signals on value, growth potential and execution risk, it makes sense to move quickly, review the full picture, and then weigh the 3 key rewards and 2 important warning signs.
Looking for more investment ideas?
If you stop here, you only see part of what the market is offering. Take a few minutes to scan other stocks and sharpen your opportunity set.
- Target potential mispricings by reviewing companies that screen as high quality with room for upside via the 48 high quality undervalued stocks.
- Strengthen the foundation of your portfolio by focusing on companies with robust finances through the solid balance sheet and fundamentals stocks screener (44 results).
- Aim to get ahead of the crowd by checking the screener containing 25 high quality undiscovered gems before others catch on.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com